Alembic Pharma rebounds, up 4% on USFDA nod to Fluorouracil injection
Shares of Alembic Pharma traded higher on Monday after the company received final approval from USFDA for its Fluorouracil Injection 2.5 g/50 mL (50 mg/mL) Pharmacy Bulk Vial.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) Pharmacy Bulk Vial. Please find enclosed herewith our press release.
Alembic Pharma falls 5% after board nod to Rs 1,150-cr impairment charges
Shares of Alembic Pharma hit a fresh 52-week low after the company's board approved Rs 1,150 crore impairment charges for three manufacturing facilities in Gujarat. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 ('SEBI LODR Regulations')
The Board of Directors ('Board') of Alembic Pharmaceuticals Limited ('Company') at its meeting held today i.e. 2nd March, 2023, has, inter alia, approved the following: (a) Impairment Review of the Capital Work-in-Progress ('CWIP') lying in the books of the Company as on 1st January, 2023. (b) Scheme of Arrangement between the Company and its shareholders. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
The Board of Directors ('Board') of Alembic Pharmaceuticals Limited ('Company') at its meeting held today i.e. 2nd March, 2023, has, inter alia, approved the following: (a) Impairment Review of the Capital Work-in-Progress ('CWIP') lying in the books of the Company as on 1st January, 2023. (b) Scheme of Arrangement between the Company and its shareholders.
Alembic Pharma gets USFDA approval to market generic cancer drug
Alembic Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market a generic breast cancer drug. The company has received approval from the US Food & Drug Administration (USFDA) to market Docetaxel Injection in multiple dose vials, the drug maker said in a statement. The company's approved product is therapeutically equivalent to Hospira Inc's drug. Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. Shares of the company were trading 0.72 per cent down at Rs 506.40 apiece on the BSE. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Docetaxel Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vial, and 80 mg/8 mL (10 mg/mL) and 160 mg/16 mL (10 mg/mL) Multiple-Dose Vials. Please find enclosed herewith our press release. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 23rd February, 2023 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company and/or their legal heir(s) for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Specimen Of The Communication Sent To The Shareholders (Both By SMS & E-Mail) Holding Shares In Physical Form In Compliance With The SEBI Circular No. SEBI/HO/OIAE/2023/03391 Dated 27Th January, 2023.
Pursuant to Regulation 30 of the Listing Regulations, 2015, please find enclosed herewith a specimen of the communication sent to the shareholders (both by SMS & E-mail) holding shares in physical form in compliance with the SEBI Circular No. SEBI/HO/OIAE/2023/03391 dated 27th January, 2023 ('SEBI Circular') informing them about the availability of dispute resolution mechanism at Stock Exchange(s). Further, in compliance with the said SEBI Circular, the Company has also placed the communication/intimation in this regard on its website at https://alembicpharmaceuticals.com/ ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company shall be meeting analysts/investors through Chasing Growth Conference hosted by Kotak Securities Limited on 20th February, 2023.